ReviewDiabetes, obesity & metabolism2026
A narrative review of meal management with the MiniMed™ 780G system: Evolution of dietary management in type 1 diabetes.
Review in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A narrative review of meal management with the MiniMed™ 780G system: Evolution of dietary management in type 1 diabetes.Diabetes, obesity & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundType 1 diabetes (T1D) meal management has long relied on structured carbohydrate counting and rigid bolus timing to achieve optimal glycaemic outcomes. However, these strategies impose a cognitive burden and are difficult to sustain in daily life. This narrative review evaluates how the MiniMed™ 780G Automated Insulin Delivery (AID) system enables revisiting management strategies with simplified and flexible approaches without significantly compromising clinical efficacy.
methodsA narrative review was conducted based on published clinical studies and real-world evidence (RWE) papers collected from MiniMed™ 780G system users. The analysis focused on meal bolusing patterns, unannounced meals, carbohydrate counting strategies, high-fat/high-protein diets, fasting regimens, and other meal-related conditions.
resultsEvidence suggests that the MiniMed™ 780G system provides significant flexibility in meal management without compromising glycaemic outcomes. Comparable time in range (TIR) was observed whether insulin was bolused pre-meal or at meal start, although delaying bolusing beyond 30 min post-meal led to greater glucose excursions. The system demonstrated the capability to compensate for missed meal boluses of up to 30 g of carbohydrates. Predefined fixed meal bolusing strategies may be more convenient for people with diabetes who are hesitant to perform precise carbohydrate counting, yet they can still achieve international glycaemic targets. Additionally, the system effectively adapts to high-fat, high-protein meals and fasting regimens, such as those observed during Ramadan, with minimal impact on TIR. Real-world data from over 61 000 users confirm that adherence to the system's optimal settings (glucose target of 100 mg/dL, active insulin time 2 h) and the use of 2-3 carbohydrate ratios per day resulted in the greatest glycaemic benefit.
conclusionThe MiniMed™ 780G system shifts the paradigm of meal management in T1D from intensive self-regulation toward automation and behavioral sustainability. These findings support broader access to AID technology by reducing reliance on precise carb counting and aligning therapy with real-world needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.